Centre intensifies regulatory surveillance over weight loss drugs

To ensure ethical pharmaceutical practices in the supply chain of weight loss drug (GLP-1), the Drugs Controller of India has intensified its regulatory surveillance against the drug’s unauthorised sale and promotion.

“With the recent introduction of multiple generic variants of GLP-1-based weight loss drugs in the Indian market, concerns have emerged regarding their on-demand availability through retail pharmacies, online platforms, wholesalers, and wellness clinics. These drugs, when used without proper medical supervision, may lead to serious adverse effects and related health risks,’’ said the Health Ministry in a release on Tuesday (March 24, 2026).

Taking cognisance of the situation, India’s drugs controller, in collaboration with State regulators, has initiated a series of targeted actions to curb possible malpractices across the pharmaceutical supply chain and prevent unauthorised sales and use.

On March 10, a comprehensive advisory was issued to all manufacturers, explicitly prohibiting surrogate advertisements and any form of indirect promotion that could mislead consumers or encourage off-label usage.

Audits, inspections

In the recent weeks, enforcement activities were significantly scaled up. Audits and inspections were conducted at 49 entities, including — online pharmacy warehouses, drug wholesalers, retailers, wellness and slimming clinics. 

These inspections spanned multiple regions across the country and focused on identifying violations related to unauthorised sale, improper prescription practices, and misleading marketing. Further, notices have also been sent to defaulting entities.

The Regulator emphasises that patient safety remains paramount. “The misuse of weight loss drugs without clinical oversight can lead to severe health complications. Citizens are advised to use such medications only under the guidance of qualified medical practitioners,’’ added the release.

It also noted that these drugs have been approved in India with condition of prescription by endocrinologists and internal medicine specialists and for some indications by cardiologists only. 

Regulatory surveillance will continue to be intensified in the coming weeks and non-compliances will be dealt with actions, including cancellation of licences, penalties, and prosecution under applicable laws, the Ministry has warned.

Monika Sharma, senior consultant, Endocrinology, Aakash Healthcare said the intensified regulation was an essential step to ensure the drug gets used by the right patients. 

“Excessive and improper use carries a real risk of complications such as gall bladder stones, risk of dehydration and protein malnutrition. Ensuring that the drug is available on prescription by a qualified medical professional will ensure that public health is ensured,” she said.